Aurinia Pharmaceuticals Inc.(AUPH)— Stock Profile, AI Score & Financials
Healthcare · Nasdaq · AI-powered stock analysis, 32-signal quality score, SEC EDGAR financials, and institutional holdings. Updated .
Aurinia Pharmaceuticals Inc. (AUPH) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. 13F Pro's AI-powered ranking engine scores AUPH at 75.2/100 on a 32-signal composite quality model, placing it at rank #101 of 2,960 stocks — the top 5% of the AI-ranked universe. AUPH scores in the top quartile across profitability (99.4), balance sheet strength (99.4), free cash flow (96.5). Areas of concern include revenue scale (30.1), which score below median versus the broader universe. Shareholder dilution risk is elevated at 24.4/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q2 2026), Aurinia Pharmaceuticals Inc. reports quarterly revenue of $83.2M, net income of $37.4M. Top institutional holders of AUPH by reported 13-F value include TANG CAPITAL MANAGEMENT, BlackRock, GOLDMAN SACHS GROUP, based on the most recent SEC filings. AUPH trades on the Nasdaq exchange and files with the SEC under CIK 1600620. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate AUPH daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Aurinia Pharmaceuticals Inc. directly from SEC EDGAR.
AI Quality Score
75.2/100
AI Rank
#101
Revenue
$83.2M
Net Income
$37.4M
AUPH key financials by period
Aurinia Pharmaceuticals Inc. reported revenue, net income and margins by fiscal period, from SEC filings.
Period
Form
Revenue
Net income
Operating margin
FY 2025
10-K
$283.1M
$287.2M
37.1%
FY 2024
10-K
$235.1M
$5.8M
-2.0%
FY 2023
10-K
$175.5M
$-78.0M
-52.2%
FY 2022
10-K
$134.0M
$-108.2M
-83.2%
FY 2021
10-K
$45.6M
$-181.0M
—
FY 2020
10-K
$50.1M
$-102.7M
—
Institutions holding AUPH
Institutional investors reporting a position in Aurinia Pharmaceuticals Inc. on SEC Form 13F.
AI-extracted from the 10-Q filed 2026-08-06 — Q2 FY2026 (quarter ended June 30, 2026). Every figure is machine-verified against the filing text on SEC EDGAR.
Total revenue rose to $83.2M on LUPKYNIS net product sales of $79.4M (+19% YoY), with net income of $37.4M after income tax expense jumped to $11.4M.
Biggest Revenue Drivers
Net product sales (LUPKYNIS)$79.4M+19% YoY
Increase in LUPKYNIS cartons sold to specialty pharmacies, driven by further lupus nephritis market penetration
License, collaboration and royalty revenue$3.8M+12% YoY
Primarily manufacturing services provided to Otsuka for sharing capacity of the Monoplant
Biggest Revenue Drivers
Total revenue: $83.2M
Net product sales (LUPKYNIS)$79.4M+19% YoY
Increase in LUPKYNIS cartons sold to specialty pharmacies, driven by further lupus nephritis market penetration
License, collaboration and royalty revenue$3.8M+12% YoY
Primarily manufacturing services provided to Otsuka for sharing capacity of the Monoplant
Largest Expense Items
Selling, general and administrative$23.5M-$2.5M YoY
Lower share-based compensation tied to March 2026 officer departures and reversals from forfeited unvested awards
Research and development$13.1M+$5.6M YoY
Higher employee-related costs supporting development activities and increased clinical supply and distribution
Cost of revenue$6.6M-7% YoY
Decrease in sales of LUPKYNIS inventory to Otsuka, which has a low gross margin
Other (income) expense, net$(6.2)Mvs $9.2M expense YoY
Favorable foreign exchange remeasurement of the Swiss Franc-denominated Monoplant finance lease liability and settlement of a former officer obligation
Margins: Gross margin was 92% for the quarter versus 90% a year earlier, as lower-margin LUPKYNIS inventory sales to Otsuka declined. Company expects SG&A to stay consistent with 2025 and R&D to increase.
Watch Items from the Filing
Revenue depends on two specialty pharmacies, one specialty distributor and partner Otsuka — all customers for accounting purposes — plus a single commercial product, LUPKYNIS.
Income tax expense rose to $11.4M from $0.6M; effective rate 23.3% versus 2.9%, as the 2025 valuation allowance release left no unrecognized deferred tax assets to offset tax.
Kezar acquisition closed May 11, 2026 for $55.5M total consideration, treated as an asset acquisition; $3.7M contingent value right liability recorded plus $23.1M deferred tax benefits.
Monoplant finance lease requires a quarterly fixed fee of CHF 3.6 million through March 31, 2030; lease liability stands at $60.4M with FX remeasurement swinging other income.
Repurchased 2.5M shares for $38.1M in the quarter ($213.4M program-to-date); $86.6M remains authorized, with no buybacks in June 2026.
AI-extracted and verified against SEC EDGAR filing text. Not investment advice.
